ARMP Soars 72% in a Month Following Infectious Disease Study Success

Armata Pharmaceuticals (ARMP) shares have skyrocketed 72.3% in the past month. The massive surge in the stock price was observed after the company announced positive top-line results from its early to mid-stage study evaluating its pipeline candidate, AP-SA02, for the treatment of Staphylococcus aureus bacteremia (SAB), earlier this week. AP-SA02 is ARMP’s novel intravenously administered multi-phage therapeutic.The phase Ib/IIa diSArm multiple ascending dose escalation study is assessing the safety, tolera ...